These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32646514)

  • 1. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.
    Boichard A; Wagner MJ; Kurzrock R
    Genome Med; 2020 Jul; 12(1):61. PubMed ID: 32646514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.
    Rosenbaum E; Antonescu CR; Smith S; Bradic M; Kashani D; Richards AL; Donoghue M; Kelly CM; Nacev B; Chan JE; Chi P; Dickson MA; Keohan ML; Gounder MM; Movva S; Avutu V; Thornton K; Zehir A; Bowman AS; Singer S; Tap W; D'Angelo S
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.
    Painter CA; Jain E; Tomson BN; Dunphy M; Stoddard RE; Thomas BS; Damon AL; Shah S; Kim D; Gómez Tejeda Zañudo J; Hornick JL; Chen YL; Merriam P; Raut CP; Demetri GD; Van Tine BA; Lander ES; Golub TR; Wagle N
    Nat Med; 2020 Feb; 26(2):181-187. PubMed ID: 32042194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
    Megquier K; Turner-Maier J; Swofford R; Kim JH; Sarver AL; Wang C; Sakthikumar S; Johnson J; Koltookian M; Lewellen M; Scott MC; Schulte AJ; Borst L; Tonomura N; Alfoldi J; Painter C; Thomas R; Karlsson EK; Breen M; Modiano JF; Elvers I; Lindblad-Toh K
    Mol Cancer Res; 2019 Dec; 17(12):2410-2421. PubMed ID: 31570656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and Future Directions for Angiosarcoma Therapy.
    Florou V; Wilky BA
    Curr Treat Options Oncol; 2018 Mar; 19(3):14. PubMed ID: 29520447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Management of Angiosarcoma: Recent Advances and Lessons From the Past.
    Florou V; Wilky BA
    Curr Treat Options Oncol; 2021 Jun; 22(7):61. PubMed ID: 34097172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
    Zhang QJ; Luan JC; Song LB; Cong R; Ji CJ; Zhou X; Xia JD; Song NH
    Front Immunol; 2021; 12():657575. PubMed ID: 33936087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma.
    Chan JY; Lim JQ; Yeong J; Ravi V; Guan P; Boot A; Tay TKY; Selvarajan S; Md Nasir ND; Loh JH; Ong CK; Huang D; Tan J; Li Z; Ng CC; Tan TT; Masuzawa M; Sung KW; Farid M; Quek RHH; Tan NC; Teo MCC; Rozen SG; Tan P; Futreal A; Teh BT; Soo KC
    J Clin Invest; 2020 Nov; 130(11):5833-5846. PubMed ID: 33016928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
    Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC/STBSG to guide the development of angiosarcoma-specific trials.
    Dufresne A; Lindner LH; Striefler J; Kasper B; Van Houdt W; Litiere S; Marreaud S; Blay JY; D'Ambrosio L; Stacchiotti S
    Eur J Cancer; 2024 Aug; 207():114188. PubMed ID: 38954898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
    Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
    Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Throughput Transcriptomics Identifies Chemoresistance-Associated Gene Expression Signatures in Human Angiosarcoma.
    Khor GMS; Haghani S; Tan TRE; Lee ECY; Kannan B; Lim BY; Lee JY; Guo Z; Ko TK; Chan JY
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma.
    Boutros C; Rouleau E; Majer M; Nikolaev S; Robert C
    Eur J Cancer; 2021 Jun; 150():130-132. PubMed ID: 33901791
    [No Abstract]   [Full Text] [Related]  

  • 14. Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
    Yan C; Richmond A
    Mol Cancer; 2021 Nov; 20(1):146. PubMed ID: 34758832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active TGF-β signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.
    Verbeke SL; Bertoni F; Bacchini P; Oosting J; Sciot R; Krenács T; Bovée JV
    Mod Pathol; 2013 Sep; 26(9):1211-21. PubMed ID: 23599148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report.
    Guan J; Luo Z; Xiao Z; Xie Y; Lin L
    BMC Cancer; 2019 Dec; 19(1):1188. PubMed ID: 31805975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.
    Huang SC; Zhang L; Sung YS; Chen CL; Kao YC; Agaram NP; Singer S; Tap WD; D'Angelo S; Antonescu CR
    Am J Surg Pathol; 2016 May; 40(5):645-55. PubMed ID: 26735859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
    Olbryt M; Rajczykowski M; Widłak W
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.
    Prenen H; Smeets D; Mazzone M; Lambrechts D; Sagaert X; Sciot R; Debiec-Rychter M
    Oncotarget; 2015 Nov; 6(34):36418-25. PubMed ID: 26474454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
    Pender A; Titmuss E; Pleasance ED; Fan KY; Pearson H; Brown SD; Grisdale CJ; Topham JT; Shen Y; Bonakdar M; Taylor GA; Williamson LM; Mungall KL; Chuah E; Mungall AJ; Moore RA; Lavoie JM; Yip S; Lim H; Renouf DJ; Sun S; Holt RA; Jones SJM; Marra MA; Laskin J
    Clin Cancer Res; 2021 Jan; 27(1):202-212. PubMed ID: 33020056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.